Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine M Tangen

Showing results (31-40 of 217) with videos related to

Pageof 22
Sort By:
Cancer|December 13, 2005
Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increaseAlan R Kristal, Chen Chi, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical TrialsCatherine M Tangen, Phyllis J Goodman, Cathee Till, et al.
Cancer|July 15, 2009
Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention TrialZhihong Gong, Alan R Kristal, Jeannette M Schenk, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 13, 2018
Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by FinasterideJames Y Dai, Michael LeBlanc, Phyllis J Goodman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approachMary W Redman, Catherine M Tangen, Phyllis J Goodman, et al.
The Journal of Urology|May 16, 2006
The prostate cancer prevention trial: design, biases and interpretation of study resultsPhyllis J Goodman, Ian M Thompson, Catherine M Tangen, et al.
Clinical Prostate Cancer|March 30, 2004
Ten-year survival in patients with metastatic prostate cancerCatherine M Tangen, James R Faulkner, E David Crawford, et al.
Clinical Trials (London, England)|August 10, 2006
Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees, Dennis O Dixon, Ralph S Freedman, et al.
Cancer|May 31, 2013
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcomeAndrew J Vickers, Daniel D Sjoberg, Donna P Ankerst, et al.
JAMA|January 18, 2006
Erectile dysfunction and subsequent cardiovascular diseaseIan M Thompson, Catherine M Tangen, Phyllis J Goodman, et al.
Pageof 22

Showing results (31-40 of 217) with videos related to

Sort By:
Pageof 22
Cancer|December 13, 2005
Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increaseAlan R Kristal, Chen Chi, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical TrialsCatherine M Tangen, Phyllis J Goodman, Cathee Till, et al.
Cancer|July 15, 2009
Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention TrialZhihong Gong, Alan R Kristal, Jeannette M Schenk, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 13, 2018
Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by FinasterideJames Y Dai, Michael LeBlanc, Phyllis J Goodman, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approachMary W Redman, Catherine M Tangen, Phyllis J Goodman, et al.
The Journal of Urology|May 16, 2006
The prostate cancer prevention trial: design, biases and interpretation of study resultsPhyllis J Goodman, Ian M Thompson, Catherine M Tangen, et al.
Clinical Prostate Cancer|March 30, 2004
Ten-year survival in patients with metastatic prostate cancerCatherine M Tangen, James R Faulkner, E David Crawford, et al.
Clinical Trials (London, England)|August 10, 2006
Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees, Dennis O Dixon, Ralph S Freedman, et al.
Cancer|May 31, 2013
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcomeAndrew J Vickers, Daniel D Sjoberg, Donna P Ankerst, et al.
JAMA|January 18, 2006
Erectile dysfunction and subsequent cardiovascular diseaseIan M Thompson, Catherine M Tangen, Phyllis J Goodman, et al.
Pageof 22